Who
Charles Cherington
10% owner
Company insider
Files Form 4 as: Director and 10% owner, Ernexa Therapeutics; 10% owner, Comera Life Sciences Holdings.
In numbers
- Trades disclosed
- 66
- Buys
- 16
- Sells
- 2
- Bought
- $9.9M
- Sold
- $6.3M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 1 Jun 2021
- Last trade
- 10 Feb 2026
- Last filed
- 17 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Feb 2026filed 17 Feb 2026 | ERNA Ernexa TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.0M4,000,000 at $0.50 | filing |
| 10 Feb 2026filed 17 Feb 2026 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —4,000,000 | filing |
| 10 Feb 2026filed 17 Feb 2026 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —4,000,000 | filing |
| 10 Feb 2026filed 17 Feb 2026 | ERNA Ernexa TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.0M4,000,000 at $0.50 | filing |
| 9 Jun 2025filed 11 Jun 2025 | ERNA Ernexa TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.1M21,241,163 at $0.10 | filing |
| 2 Apr 2025filed 4 Apr 2025 | ERNA Ernexa TherapeuticsBiotechnology | SEC FORM 4 Bought | $377K3,768,397 at $0.10 | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | — | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | — | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | — | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | — | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | — | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | — | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa TherapeuticsBiotechnology | SEC FORM 4 Bought | —261,756 | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa TherapeuticsBiotechnology | SEC FORM 4 Bought | —4,768,783 | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa TherapeuticsBiotechnology | SEC FORM 4 Bought | —1,237,762 | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa TherapeuticsBiotechnology | SEC FORM 4 Bought | —5,420,823 | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa TherapeuticsBiotechnology | SEC FORM 4 Bought | —1,562,988 | filing |
| 29 Oct 2024filed 5 Nov 2024 | ERNA Ernexa TherapeuticsBiotechnology | SEC FORM 4 Code C | $1.4M2,819,546 at $0.50 | filing |
| 24 Sep 2024filed 7 May 2025 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —523,512 | filing |
| 24 Sep 2024filed 7 May 2025 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —2,475,524 | filing |
News
Ernexa Therapeutics Focuses On Clinical Readiness Of Lead Cancer CandidateERNA · rttnews.com · 22 Oct 2026Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New "What This Means" SegmentERNA · manilatimes.net · 22 Oct 2026Ernexa Therapeutics to Participate in Virtual Investor Closing Bell SeriesERNA · manilatimes.net · 12 Oct 2026
0 headlines in the last 90 days name Charles Cherington; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.